VRTX•prnewswire•
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
Summary
SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 3, 2026 by prnewswire